27,780 Alzheimer's and dementia studies in plain English, each scored out of 100.
Ninety-five individuals from the Wisconsin Registry for Alzheimer's Prevention were included in these cross-sectional analyses. 4 key findings →
Design: cross-sectional Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
The independent and combined effects of physical and cognitive domains of frailty in predicting the development of mild cognitive impairment (MCI) or dementia are not firmly established. 2 key findings →
Design: cross-sectional Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Goal To examine dementia characteristics, age at onset and associated co-morbidities in persons with Down syndrome. 4 key findings →
Participants: 77 Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
From the 144 participants (56.3% female and 43.7% male, with a mean [standard deviation] age of 80.7 [7.7] years), 118 participants were available for final follow-up. 4 key findings →
Design: cohort study Participants: 144 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
The findings from this study have the potential to significantly enhance efforts to ameliorate cognitive aging and slow dementia. 2 key findings →
Participants: 360 Evidence: high
Full summary, score breakdown and related studies → Original source
Whilst nursing home managers recognise the potential benefits of advance care planning, barriers and challenges create a reluctance to facilitate. 3 key findings →
Design: cross-sectional Participants: 178 Evidence: low
Full summary, score breakdown and related studies → Original source
Approximately one-third of the Medicare beneficiaries who died in 2011 had four or more transitions within their last 6 months of life. 3 key findings →
Participants: 660,132 Evidence: low
Full summary, score breakdown and related studies → Original source
These findings are consistent with reports that care homes can provide care akin to hospice for the very old and support an approach of supporting residents to stay in their care home or own home if possible. 3 key findings →
Participants: 180 Evidence: moderate
Full summary, score breakdown and related studies → Original source
This study indicates the need to provide nurses and nursing assistants with more information about palliative care practice for people with advanced dementia. 2 key findings →
Design: cross-sectional Participants: 125 Evidence: low
Full summary, score breakdown and related studies → Original source
Dichotomising these biomarkers as normal or abnormal results in eight possible profiles. 2 key findings →
Participants: 435 Evidence: low
Full summary, score breakdown and related studies → Original source
Chronic, low-grade inflammation, or inflammaging, is a crucial contributor to various age-related pathologies and natural processes in aging tissue, including the nervous system. 1 key finding →
Design: cohort study Evidence: moderate
Full summary, score breakdown and related studies → Original source
A discussion with theoretical and possible future research directions is provided and it is clear that the need is not only of longitudinal population studies and of better knowledge of epigenetics markers but, especially, of environmental policy interventions based on the green economy. 3 key findings →
Design: longitudinal study Evidence: moderate
Full summary, score breakdown and related studies → Original source
Earlier AutD is associated with a more rapid development of disease milestones and shorter survival in patients with PD. 5 key findings →
Participants: 100 Evidence: low
Full summary, score breakdown and related studies → Original source
All amyloid negative subjects imaged were tau-negative. 5 key findings →
Design: cohort study Evidence: moderate
Full summary, score breakdown and related studies → Original source
Utilizing [18F]-AV-1451 tau positron emission tomography (PET) as an Alzheimer disease (AD) biomarker will require identification of brain regions that are most important in detecting elevated tau pathology in preclinical AD. 1 key finding →
Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
An acquisition protocol using time windows of 0-30 and 120-140 min with appropriate interpolation of the missing time points provided the best compromise between patient comfort and quantification accuracy. 5 key findings →
Design: longitudinal study Participants: 20 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
The apolipoprotein E (APOE) gene is the strongest genetic risk factor for late-onset Alzheimer disease. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Olfactory identification deficit is a useful screening tool for AD-related amnestic disorder, with sensitivity and specificity comparable to other established biomarkers, with benefits such as ease of administration and low cost. 1 key finding →
Design: cross-sectional Participants: 96 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Recent research has linked age-related hearing loss to impaired performance across cognitive domains and increased risk for dementia diagnosis. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
As the population ages due to demographic trends and gains in life expectancy, the incidence and prevalence of dementia increases, and the need to understand the etiology and pathogenesis of dementia becomes ever more urgent. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
A projected doubling in the global population of people aged ≥60 y by the year 2050 has major health and economic implications, especially in developing regions. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Alzheimer disease (AD) is the most common type of dementia, and is currently incurable; existing treatments for AD produce only a modest amelioration of symptoms. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
The AD drug development pipeline has 105 agents divided among phase I, phase II, and phase III. 2 key findings →
Participants: 54,073 Evidence: low
Full summary, score breakdown and related studies → Original source
Disease-specific patterns of functional network topology and connectivity alterations were observed in patients with EOAD and bvFTD. 3 key findings →
Participants: 37 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Caregivers of care recipients without dementia or disability accounted for the largest absolute number of helpers. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 27,780 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,780 records, built mostly from automated pulls of Europe PMC (61.1% of the library) and OpenAlex (18.3%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,034 records (3.7% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →